A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)

Exclusion Criteria

• •Other forms of vitiligo or skin depigmentation disorders.
• •Clinically significant abnormal TSH or free T4 at screening.
• •Use of laser or phototherapy within 8 weeks and dihydroxyacetone within 4 weeks prior to Day 1.
• •Current or past use of the depigmenting agent monobenzyl ether of hydroquinone including Benoquin®.
• •History of melanocyte-keratinocyte transplantation procedure or other surgical treatment for vitiligo.
• •Spontaneous and significant repigmentation within 6 months prior to screening.
• •Women who are pregnant, considering pregnancy, or breast feeding.
• •Medical history including thrombocytopenia, coagulopathy or platelet dysfunction; venous and arterial thrombosis, deep vein thrombosis, pulmonary embolism, stroke, moderate to severe heart failure, cerebrovascular accident, myocardial infarction, or other significant cardiovascular diseases; Q-wave interval abnormalities; disseminated herpes zoster or recurrent dermatomal herpes zoster; disseminated herpes simplex; chronic/recurrent infections; malignancies.
• •Evidence of infection with TB, HBV, HCV or HIV.
• •History of failure to JAK inhibitor treatment of any inflammatory disease.
• •Laboratory values outside of the protocol-defined ranges.